Core Laboratories opened higher at $9.07, compared with its previous close of $9.04. In the last trading session, the stock traded between $8.97 and $9.27. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Core Laboratories is now worth
$ 34.02
Resulting in a loss of
$ 65.98 (65.98%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
0%
Hold
0%
Sell
100%
Markets Today
Today's Change
$-0.03 (-0.29%)
Day High
$9.27
Day Low
$8.97
Day Open
$9.07
Prev Close
$9.04
Volume
3,92,334
1W Return
-6.72%
1M Return
-9.77%
3M Return
-27.47%
6M Return
-32.23%
1Y Return
-44.19%
Fundamentals
Market Cap ($ Mn)
413
PE Ratio
23.77
PB Ratio
2.08
PEG Ratio
3.13
ROE
11.70%
ROCE
11.56%
EPS (TTM)
$0.12
Investment Returns
1 Week
-6.72%
1 Month
-9.77%
3 Months
-27.47%
6 Months
-32.23%
9 Months
-52.41%
Financials
Quarterly
All values in $ Mn
130.2
Jun 25
134.5
Sep 25
138.3
Dec 25
121.8
Mar 26
124.6
Jun 26
132.1
Sep 26
Updates
2Oct
Core Laboratories sets Oct 29 call for Q3FY26 results
Core Laboratories schedules Q3FY26 earnings call for October 29, 2026. Press release to be issued after market close on October 28, 2026. Larry Bruno, Chris Hill, and Gwen Gresham to lead the discussion. Webcast registration required 15 minutes before call start time.
1mo ago
30Jul
Core Laboratories Q2 adj EPS $0.11 beats estimate
Core Laboratories reported Q2 2026 adjusted EPS of $0.11, beating analyst estimates of $0.09 by 22.22%. Revenue of $124.6 million missed expectations slightly but operating income rose 385% sequentially to $9.2 million, aided by strong performance in the Production Enhancement segment which offset geopolitical headwinds in Reservoir Description.
Core Laboratories Q3 guidance misses analyst estimates for both EPS and sales. The company forecasts GAAP EPS of $0.12-$0.20 versus a $0.16 estimate, and sales of $128.5M-$135.5M against a $131.33M forecast, indicating potential operational headwinds.
